PC
ABEO icon

PointState Capital’s Abeona Therapeutics ABEO Stock Holding History

PointState Capital’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-23,024
Closed -$9.21M – 139
2018
Q2 		$9.21M Buy
+23,024
New +$10.1M 0.1% 105
2017
Q4 		– Sell
-15,120
Closed -$6.45M – 154
2017
Q3 		$6.45M Buy
+15,120
New +$4.06M 0.05% 123

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

PointState Capital's ABEO Position: Q3 2018 in Review

PointState Capital sold out of Abeona Therapeutics (ABEO) in Q3 2018, closing a stake of 23,024 shares — an estimated $9.21M sold.

PointState Capital first reported a position in ABEO in Q3 2017 and held it in 2 quarters. The position peaked at $9.21M in Q2 2018. 104 funds tracked by Wall St. Rank hold ABEO as of Q3 2018.

  • PointState Capital reported no remaining Abeona Therapeutics position as of Q3 2018 after selling out during the quarter.
  • PointState Capital sold 23,024 Abeona Therapeutics shares in Q3 2018, an estimated $9.21M.
  • PointState Capital first reported a position in Abeona Therapeutics in Q3 2017 and held it in 2 quarters.
  • PointState Capital's Abeona Therapeutics position peaked at $9.21M in Q2 2018.
  • 104 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.